Summer e-Update: Women's Health Highlights from FDA Office of Women's Health

["FDA Office of Women's Health" <fda@xxxxxxxxxxxxxxxxxxxxxxx>]

Title: Summer e-Update: Women's Health Highlights from FDA Office of Women's Health

June/ July 2015
www.fda.gov/womens

Message from the Director

Throughout the summer, FDA is busy working to keep you safe. In this update, we highlight some of the Agency’s ongoing efforts to monitor the safety of products used by women including birth control and cosmetics. There are also links to FDA resources on HIV, sun safety, and nutrition. Whether you are on vacation or at the office, I encourage you to look to FDA for the health information that can help both you and your family.

 

Marsha Henderson

Assistant Commissioner for Women’s Health

FDA Women's Health highlights

Essure

Essure is a permanent birth control method for women (female sterilization). FDA takes reports of problems with Essure very seriously. The agency is actively evaluating postmarket experiences with this device. Public Meeting FDA plans to convene a public meeting of the Obstetrics and Gynecology Devices Panel on September 24, 2015 to discuss scientific data regarding Essure’s safety and effectiveness. At this meeting, the FDA invites feedback from presenters, panel members and the public to inform recommendations and next steps about Essure.

New Essure Webpage

FDA is committed to keeping patients and health care providers informed by sharing information as it becomes available. FDA updated its Essure Web Page to include information for patients and health care providers.

 Learn more about Essure Permanent Birth Control

FDA Guidance on Pregnancy, Lactation, and Reproductive Potential Labeling

This guidance is intended to help small businesses better understand and comply with the new content and format requirements of the Pregnancy, Lactation, and Females and Males of Reproductive Potential subsections of labeling for human prescription drug and biological products. Read the Guidance (PDF 164KB).

How to Report a Problem with Cosmetics

Cosmetic products range from lipstick and nail polish to deodorant and hairspray. While many people don’t have any problems after using cosmetics, reactions sometimes occur. FDA wants to know if you’ve had a reaction to a cosmetic product. You can report any reaction related to a cosmetic, from a minor rash or headache to an illness that put you in the hospital. You can even report something that didn’t cause a reaction, but alerted you to a problem with the product, such as a bad smell or other sign of contamination. A consumer, a health care provider, or a salon professional can report a problem. It helps if only one person files a report on each incident Learn 2 ways to report a problem with a cosmetic to FDA Get helpful tips on safely using cosmetics

Extras

Should You Put Sunscreen on Infants? Not Usually

Babies' skin is less mature compared to adults, and infants have a higher surface-area to body-weight ratio compared to older children and adults. Both these factors mean that an infant's exposure to the chemicals in sunscreens may be much greater, increasing the risk of side effects from the sunscreen. The best protection is to keep your baby in the shade, if possible.

Get other Sun Safety Tips for Infants

Learn the ABCs of Sun Protection

HIV Testing Resources

June 27th is National HIV Testing Day. FDA has resources that you can use at your events to help educate women about HIV testing, prevention, and treatment.

Download a Women and HIV fact sheet

Learn more about FDA’s role in HIV Testing

Find a free and confidential HIV testing site near you

FDA Cuts Trans Fat in Processed Foods

FDA finalized its determination that partially hydrogenated oils (PHOs), the primary dietary source of artificial trans fat in processed foods, are not “generally recognized as safe” or GRAS for use in human food. Food manufacturers will have three years to remove PHOs from products.

Read a Consumer Article on Trans Fats

FDA Meetings

Drug Safety and Risk Management Advisory Committee and Anesthetic and Analgesic Drug Products Advisory Committee

July 7-8, 2015

FDA White Oak Campus, Silver Spring, MD

The committees will discuss the results of post marketing studies evaluating the misuse and/or abuse of reformulated OXYCONTIN (oxycodone hydrochloride) extended-release tablets, supplemental new drug application.

OWH Conference Calendar

The Office of Women’s Health exhibits and presents at conferences across the country to increase awareness of FDA’s women’s health resources and programs. Check out an OWH exhibit booth or presentation at one of these conferences:

YWCA, June 4-6 – Washington, DC

American Association of Nurse Practitioners, June 9-12 – New Orleans, LA

American Library Association*, June 25-30 – San Francisco, CA

American College of Nurse-Midwives, June 28—National Harbor, MD

Teratology Society, June 27-July 1 – Montreal, Canada

National Association of Hispanic Nurses*, July 7-10 – Anaheim, CA

National Council of La Raza*, July 11-14 – Kansas City, MO

American Association of Colleges of Pharmacy, July 11-15 – National Harbor, MD

National Area Agencies on Aging*, July 11-15 – Philadelphia, PA

Delta Sigma Theta National Public Service Convention, July 23-29 – Houston, TX

National Black Nurses Association*, July 29- August2 – Atlanta, GA

 

*Come meet the local FDA Public Affairs Staff who support our women’s health field outreach.

Please share this update with your network, members, constituents, and community

 

FDA Office of Women's Health

10903 New Hampshire Avenue

WO32 - Room 2333

Silver Spring, MD 20993*0002

301-796-9440

 

Report a Problem with a Medical Product

---

Subscriber Services:
Manage Preferences  |  Unsubscribe  |  Help with this service

Stay Connected:

---

This email was sent to list-fda@xxxxxxxxxxx using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420